Literature DB >> 23036045

Ageing and long-term CD4 cell count trends in HIV-positive patients with 5 years or more combination antiretroviral therapy experience.

S T Wright1, K Petoumenos, M Boyd, A Carr, S Downing, C C O'Connor, M Grotowski, M G Law.   

Abstract

OBJECTIVES: The aim of this study was to describe the long-term changes in CD4 cell counts beyond 5 years of combination antiretroviral therapy (cART). If natural ageing leads to a long-term decline in the immune system via low-grade chronic immune activation/inflammation, then one might expect to see a greater or earlier decline in CD4 counts in older HIV-positive patients with increasing duration of cART.
METHODS: Retrospective and prospective data were examined from long-term virologically stable HIV-positive adults from the Australian HIV Observational Database. We estimated mean CD4 cell count changes following the completion of 5 years of cART using linear mixed models.
RESULTS: A total of 37 916 CD4 measurements were observed for 892 patients over a combined total of 9753 patient-years. Older patients (> 50 years old) at cART initiation had estimated mean (95% confidence interval) changes in CD4 counts by year-5 CD4 count strata (< 500, 500-750 and > 750 cells/μL) of 14 (7 to 21), 3 (-5 to 11) and -6 (-17 to 4) cells/μL/year. Of the CD4 cell count rates of change estimated, none were indicative of long-term declines in CD4 cell counts.
CONCLUSIONS: Our results suggest that duration of cART and increasing age do not result in decreasing mean changes in CD4 cell counts for long-term virologically suppressed patients, indicating that the level of immune recovery achieved during the first 5 years of treatment is sustained through long-term cART.
© 2012 British HIV Association.

Entities:  

Mesh:

Year:  2012        PMID: 23036045      PMCID: PMC3556360          DOI: 10.1111/j.1468-1293.2012.01053.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  27 in total

Review 1.  Premature ageing of the immune system: the cause of AIDS?

Authors:  Victor Appay; Sarah L Rowland-Jones
Journal:  Trends Immunol       Date:  2002-12       Impact factor: 16.687

2.  Premature Aging and Premature Age-Related Comorbidities in HIV-Infected Patients: Facts and Hypotheses.

Authors:  Jacqueline Capeau
Journal:  Clin Infect Dis       Date:  2011-10-13       Impact factor: 9.079

Review 3.  Immunological recovery and antiretroviral therapy in HIV-1 infection.

Authors:  Manuel Battegay; Reto Nüesch; Bernard Hirschel; Gilbert R Kaufmann
Journal:  Lancet Infect Dis       Date:  2006-05       Impact factor: 25.071

4.  Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs.

Authors:  V Le Moing; R Thiébaut; G Chêne; A Sobel; P Massip; F Collin; Mc Meyohas; F Al Kaïed; C Leport; F Raffi
Journal:  HIV Med       Date:  2007-04       Impact factor: 3.180

5.  CD4 cell responses to combination antiretroviral therapy in patients starting therapy at high CD4 cell counts.

Authors:  Stephen T Wright; Andrew Carr; Ian Woolley; Michelle Giles; Jennifer Hoy; David A Cooper; Matthew G Law
Journal:  J Acquir Immune Defic Syndr       Date:  2011-09-01       Impact factor: 3.731

6.  CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy.

Authors:  Xiuhong Li; Joseph B Margolick; Beth D Jamieson; Charles R Rinaldo; John P Phair; Lisa P Jacobson
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08-15       Impact factor: 3.731

7.  BELFAST nonagenarians: nature or nurture? Immunological, cardiovascular and genetic factors.

Authors:  I M Rea
Journal:  Immun Ageing       Date:  2010-05-27       Impact factor: 6.400

8.  Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.

Authors:  Peter W Hunt; Steven G Deeks; Benigno Rodriguez; Hernan Valdez; Starley B Shade; Donald I Abrams; Mari M Kitahata; Melissa Krone; Torsten B Neilands; Richard J Brand; Michael M Lederman; Jeffrey N Martin
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

9.  CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater.

Authors:  Luuk Gras; Anouk M Kesselring; James T Griffin; Ard I van Sighem; Christophe Fraser; Azra C Ghani; Frank Miedema; Peter Reiss; Joep M A Lange; Frank de Wolf
Journal:  J Acquir Immune Defic Syndr       Date:  2007-06-01       Impact factor: 3.731

Review 10.  HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.

Authors:  Margaret T May; Jonathan A C Sterne; Dominique Costagliola; Caroline A Sabin; Andrew N Phillips; Amy C Justice; François Dabis; John Gill; Jens Lundgren; Robert S Hogg; Frank de Wolf; Gerd Fätkenheuer; Schlomo Staszewski; Antonella d'Arminio Monforte; Matthias Egger
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

View more
  13 in total

1.  Trends in CD4 cell count response to first-line antiretroviral treatment in HIV-positive patients from Asia, 2003-2013: TREAT Asia HIV Observational Database Low Intensity Transfer.

Authors:  Nicole L De La Mata; Penh S Ly; Oon T Ng; Kinh V Nguyen; Tuti P Merati; Thuy T Pham; Man P Lee; Jun Y Choi; Annette H Sohn; Matthew G Law; Nagalingeswaran Kumarasamy
Journal:  Int J STD AIDS       Date:  2017-03-21       Impact factor: 1.359

2.  National characteristics and trends in antiretroviral treatment in Australia can be accurately estimated using a large clinical cohort.

Authors:  Robin Huang; Kathy Petoumenos; Richard T Gray; Hamish McManus; Nila Dharan; Rebecca Guy; David A Cooper
Journal:  J Clin Epidemiol       Date:  2018-04-25       Impact factor: 6.437

3.  HIV and aging: insights from the Asia Pacific HIV Observational Database (APHOD).

Authors:  N Han; S T Wright; C C O'Connor; J Hoy; S Ponnampalavanar; M Grotowski; H X Zhao; A Kamarulzaman
Journal:  HIV Med       Date:  2014-11-18       Impact factor: 3.180

4.  Vascular cognitive impairment and HIV-associated neurocognitive disorder: a new paradigm.

Authors:  Lucette A Cysique; Bruce J Brew
Journal:  J Neurovirol       Date:  2019-01-11       Impact factor: 2.643

5.  CD4+/CD8+ ratio, age, and risk of serious noncommunicable diseases in HIV-infected adults on antiretroviral therapy.

Authors:  Jessica L Castilho; Bryan E Shepherd; John Koethe; Megan Turner; Sally Bebawy; James Logan; William B Rogers; Stephen Raffanti; Timothy R Sterling
Journal:  AIDS       Date:  2016-03-27       Impact factor: 4.177

6.  Association of Viral Suppression With Lower AIDS-Defining and Non-AIDS-Defining Cancer Incidence in HIV-Infected Veterans: A Prospective Cohort Study.

Authors:  Lesley S Park; Janet P Tate; Keith Sigel; Sheldon T Brown; Kristina Crothers; Cynthia Gibert; Matthew Bidwell Goetz; David Rimland; Maria C Rodriguez-Barradas; Roger J Bedimo; Amy C Justice; Robert Dubrow
Journal:  Ann Intern Med       Date:  2018-06-12       Impact factor: 25.391

7.  Recent trends in early stage response to combination antiretroviral therapy in Australia.

Authors:  Hamish McManus; Jennifer F Hoy; Ian Woolley; Mark A Boyd; Mark D Kelly; Brian Mulhall; Norman J Roth; Kathy Petoumenos; Matthew G Law
Journal:  Antivir Ther       Date:  2014-04-04

8.  CD4 Response Up to 5 Years After Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients in Latin America and the Caribbean.

Authors:  Paula M Luz; Pablo F Belaunzarán-Zamudio; Brenda Crabtree-Ramírez; Yanink Caro-Vega; Daniel Hoces; Peter F Rebeiro; Meridith Blevins; Jean W Pape; Claudia P Cortes; Denis Padgett; Pedro Cahn; Valdilea G Veloso; Catherine C McGowan; Beatriz Grinsztejn; Bryan E Shepherd
Journal:  Open Forum Infect Dis       Date:  2015-06-05       Impact factor: 3.835

9.  Modeling Outcomes of First-Line Antiretroviral Therapy and Rate of CD4 Counts Change among a Cohort of HIV/AIDS Patients in Ethiopia: A Retrospective Cohort Study.

Authors:  Tadesse Awoke; Alemayehu Worku; Yigzaw Kebede; Adetayo Kasim; Belay Birlie; Roel Braekers; Khangelani Zuma; Ziv Shkedy
Journal:  PLoS One       Date:  2016-12-20       Impact factor: 3.240

10.  Factors associated with prognostic or treatment outcomes in HIV/AIDS patients with and without hypertension in Eswatini.

Authors:  Sabelo Bonginkosi Dlamini; Hans-Uwe Dahms; Ming-Tsang Wu
Journal:  Sci Rep       Date:  2021-06-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.